Jpmorgan Chase & CO Intra Cellular Therapies, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 5,286,285 shares of ITCI stock, worth $460 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
5,286,285
Previous 3,435,232 53.88%
Holding current value
$460 Million
Previous $235 Million 64.29%
% of portfolio
0.03%
Previous 0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024
BUY
$67.99 - $80.84 $126 Million - $150 Million
1,851,053 Added 53.88%
5,286,285 $387 Million
Q2 2024

Aug 12, 2024
BUY
$64.76 - $79.84 $109 Million - $134 Million
1,679,284 Added 95.63%
3,435,232 $235 Million
Q1 2024

May 10, 2024
SELL
$64.37 - $75.65 $20.4 Million - $24 Million
-316,667 Reduced 15.28%
1,755,948 $122 Million
Q4 2023

Feb 12, 2024
BUY
$46.37 - $73.65 $408,658 - $649,077
8,813 Added 0.43%
2,072,615 $148 Million
Q3 2023

Nov 14, 2023
BUY
$52.09 - $64.1 $4.5 Million - $5.54 Million
86,388 Added 4.37%
2,063,802 $108 Million
Q2 2023

Aug 11, 2023
BUY
$54.67 - $66.44 $8.01 Million - $9.74 Million
146,530 Added 8.0%
1,977,414 $125 Million
Q1 2023

May 18, 2023
BUY
$43.8 - $56.99 $5.23 Million - $6.8 Million
119,387 Added 6.98%
1,830,884 $99.1 Million
Q1 2023

May 11, 2023
BUY
$43.8 - $56.99 $9.35 Million - $12.2 Million
213,583 Added 14.26%
1,711,497 $92.7 Million
Q4 2022

Feb 13, 2023
BUY
$44.07 - $54.45 $57.7 Million - $71.3 Million
1,310,130 Added 697.68%
1,497,914 $79.3 Million
Q3 2022

Nov 14, 2022
SELL
$42.7 - $59.99 $61,189 - $85,965
-1,433 Reduced 0.76%
187,784 $8.74 Million
Q2 2022

Aug 11, 2022
BUY
$43.0 - $65.64 $1.38 Million - $2.11 Million
32,073 Added 20.41%
189,217 $10.8 Million
Q1 2022

May 11, 2022
BUY
$38.74 - $62.09 $637,427 - $1.02 Million
16,454 Added 11.7%
157,144 $9.62 Million
Q4 2021

Feb 10, 2022
SELL
$35.2 - $53.42 $46,217 - $70,140
-1,313 Reduced 0.92%
140,690 $7.36 Million
Q3 2021

Nov 12, 2021
BUY
$28.72 - $42.49 $4.08 Million - $6.03 Million
142,003 New
142,003 $5.29 Million

Others Institutions Holding ITCI

# of Institutions
378
Shares Held
84.7M
Call Options Held
319K
Put Options Held
143K
View Full List

About Intra-Cellular Therapies, Inc.

ITCI Quotes by TradingView
  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $8.21B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email